Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation by Evelyn Ullrich et al.
December 2016 | Volume 7 | Article 5951
Original research
published: 22 December 2016
doi: 10.3389/fimmu.2016.00595
Frontiers in Immunology | www.frontiersin.org
 
Edited by: 
Antoine Toubert, 
Paris Diderot University, France
Reviewed by: 
Norberto Walter Zwirner, 
Institute of Biology and Experimental 
Medicine (IBYME-CONICET), 
Argentina  
Nicholas D. Huntington, 
Walter and Eliza Hall Institute of 
Medical Research, Australia
*Correspondence:
Evelyn Ullrich  
evelyn.ullrich@kgu.de
†These authors have contributed 
equally to this work.
Specialty section: 
This article was submitted to 
Alloimmunity and Transplantation, 
a section of the journal 
Frontiers in Immunology
Received: 03 July 2016
Accepted: 30 November 2016
Published: 22 December 2016
Citation: 
Ullrich E, Salzmann-Manrique E, 
Bakhtiar S, Bremm M, Gerstner S, 
Herrmann E, Bader P, Hoffmann P, 
Holler E, Edinger M and Wolff D 
(2016) Relation between Acute 
GVHD and NK Cell Subset 
Reconstitution Following Allogeneic 
Stem Cell Transplantation. 
Front. Immunol. 7:595. 
doi: 10.3389/fimmu.2016.00595
relation between acute gVhD and 
nK cell subset reconstitution 
Following allogeneic stem cell 
Transplantation
Evelyn Ullrich1,2*†, Emilia Salzmann-Manrique2†, Shahrzad Bakhtiar2†, Melanie Bremm2, 
Stephanie Gerstner1, Eva Herrmann3, Peter Bader1,2, Petra Hoffmann4,5, Ernst Holler4,5, 
Matthias Edinger4,5 and Daniel Wolff4,5
1 LOEWE Center for Cell and Gene Therapy, Goethe University, Frankfurt, Germany, 2 Division for Stem Cell Transplantation 
and Immunology, Department for Children and Adolescents Medicine, Hospital of the Goethe University Frankfurt, Frankfurt, 
Germany, 3 Institute of Biostatistics and Mathematical Modeling, Johann Wolfgang Goethe University, Frankfurt, Germany, 
4 Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany, 5 Regensburg Center for 
Interventional Immunology (RCI), University of Regensburg, Regensburg, Germany
One of the major challenges of allogeneic stem cell transplantation (allo-SCT) is to 
reduce the risk of graft-versus-host disease (GVHD) while boosting the graft-versus-
leukemia (GVL) effect. The reconstitution of natural killer (NK) cells following allo-SCT is 
of notable interest due to their known capability to induce GVL without GVHD. Here, in 
this study, we investigate the association between the incidence and severity of acute 
graft-versus-host disease (aGVHD) and the early reconstitution of NK cell subsets 
following allo-SCT. We analyzed 342 samples from 107 patients using flow cytometry, 
with a focus on immature CD56high and mature cytotoxic CD56dim NK cells. Longitudinal 
analysis of immune reconstitution after allo-SCT showed that the incidence of aGVHD 
was associated with a delayed expansion of the entire NK cell population, in particular 
the CD56high subset. Notably, the disturbed reconstitution of the CD56high NK cells also 
correlated with the severity of aGVHD.
Keywords: nK cell, nK cell subset, gVhD, scT, immune reconstitution
inTrODUcTiOn
Allogeneic stem cell transplantation (allo-SCT) often remains the only curative treatment for hema-
tological disorders. However, its success is frequently limited by acute and chronic graft-versus-host 
disease (GVHD), causing significant morbidity and mortality (1). One of the major challenges of 
allo-SCT is to reduce the incidence and severity of GVHD while boosting the graft-versus-leukemia 
(GVL) effect. In the setting of allo-SCT, the reconstitution of natural killer (NK) cells is of notable 
interest due to their known capability to induce GVL without GVHD (2). NK cells are known to 
play an important role in innate and adaptive immunity as well as in immunotherapeutic approaches 
(3–5). Recently, we could demonstrate that NK cells gain cytotoxic and cytokine producing functions 
early during hematopoietic immune reconstitution following autologous SCT (6). In addition to 
clinical studies, it has been shown in animal models that IL-2-activated NK cells may efficiently 
prevent or even reduce GVHD without any adverse impact on their important GVL effect (7–9). In 
humans, KIR mismatch in haploidentical BMT in the GVH direction reduced the risk of GVHD 
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(2, 10), and adaptive cell therapies using expanded NK cells have 
been established for different malignancies and for the relapse of 
leukemia (3, 5, 11, 12).
However, NK cells are a heterogeneous population that can 
be classified into phenotypically and functionally distinct subsets 
(9, 13, 14). Recently, we demonstrated in a mouse allo-SCT and 
GVHD model that the mature subset of fully cytotoxic NK cells 
specifically mediates both the antitumor (GVL) and the GVHD-
reducing effects (9).
In line with this finding, it is well known that NK cell recon-
stitution following allo-SCT correlates with higher numbers of 
immature CD56highCD16dim NK cells that further differentiate 
into cytotoxic CD56dimCD16high NK cells (15–17). While immune 
reconstitution per  se has been shown to be influenced by the 
occurrence of acute graft-versus-host disease (aGVHD) and 
chronic GVHD and the need for immunosuppressive treatment 
(18), it is not yet completely known to which extent early NK cell 
reconstitution is influenced by the occurrence of aGVHD.
Here, in our single-center immune monitoring study 
performed at the University Hospital Regensburg, we inves-
tigated the possible correlation between the regeneration of 
NK cell subsets and the incidence of aGVHD during the first 
200  days following allo-SCT, with a focus on immature NK 
cells (CD14−CD3−CD56highCD16dim), mature cytotoxic NK cells 
(CD14−CD3−CD56dimCD16high), and the ratio of these two popu-
lations (CD56dim:CD56high).
MaTerials anD MeThODs
study Design and sample collection
This study was approved by the Ethics committee of the University 
Regensburg, Germany (approval no. 02/220) and carried out 
in accordance to the Declaration of Helsinki. All subjects gave 
written informed consent in accordance with the Declaration of 
Helsinki. In this study, data were collected from 2009 to 2012. In 
sum, 107 patients were included into this study. Patient character-
istics are described in Table 1. HLA typing was always performed 
with the same strategy using high resolution HLA-A, B, DR, 
and DQ for sibling and additional HLA-C typing for unrelated 
donors according to the standard of the European Federation for 
Immunogenetics.
Patient blood samples were collected prior to and following 
allo-SCT at different time points during regular outpatients visits. 
The frequency of sample collection was part of the individual 
follow-up plan for each patient at fixed time points and addition-
ally when specific events occurred during the first 200 days after 
their treatment by allo-SCT. Exclusion criteria were the develop-
ment of chronic GVHD or an overlap syndrome with signs of 
both acute and chronic GVHD.
Peripheral blood mononuclear cells of each sample were 
freshly isolated by density gradient centrifugation (Pancoll 
human, Pan-Biotech) and within 24 h analyzed by flow cytometry 
(FACS). Samples of healthy controls were processed in exactly the 
same way as patient samples. The following antibodies were used: 
CD3-FITC (SK7), CD16-PE (B73.1), CD14-PerCP (MΦP9), and 
CD56-APC (N-CAM 16-2), all from BD Biosciences. The focus 
of this analysis was on immature CD56high and mature cytotoxic 
CD56dim NK cells. At each time point, patients were considered 
to be “with aGVHD” or “without aGVHD” based on clinical find-
ings. The evaluation of aGVHD was performed on a weekly basis 
applying the modified Keystone and NIH criteria (19, 20). All 
patients suffering from aGVHD, at least at one sample drawing, 
were included in the aGVHD group, those without any signs of 
aGVHD at any sampling time point were included in the group 
without aGVHD.
statistical considerations
First, patient characteristics were summarized (Table 1) and the 
Fisher-Exact test or Mann–Whitney test was used as appropri-
ate for comparisons. Classification of GVHD was performed 
according to the NIH consensus criteria (20). Additionally, the 
cumulative incidence (CI) of aGVHD has been assessed consid-
ering relapse and death without relapse as competing event. In the 
same way, we analyzed the CI considering the grade of aGVHD.
With the aim to perform a longitudinal analysis of the NK cell 
numbers associated with aGVHD development and severity, a 
mixed effect regression model with a linear spline model was used. 
The reconstitution profile analyzed in this study comprised the 
dynamics of absolute values of NK cells, CD56high cells, CD56dim 
cells, and the ratio CD56dim cells:CD56high cells within the first 
200 days after allo-SCT. Patients were previously classified into 
two groups according to their clinical and laboratory findings of 
aGVHD as described before. All measurements from patients who 
did not develop any signs of aGVHD at any collection time point 
measured during 200 days following allo-SCT were included in 
the longitudinal analysis. For patients who developed aGVHD 
during the 200 days period after allo-SCT, data measured from 
allo-SCT until achievement of aGVHD remission were included 
in the analysis. For each NK subset, the incidence of aGVHD 
and the severity of aGVHD were considered separately to be 
dependent variables. Furthermore, to evaluate the effect of steroid 
administration on NK cell reconstitution, the aGVHD patients 
were classified regarding GVHD stage and steroid treatment (ST) 
at each observation. Afterward, linear spline regression models 
were fitted separately for each NK cell subpopulation.
To optimize the residual distribution of the regression analysis, 
cell counts of NK subsets and the analyzed ratio were previously 
log10-transformed. Note that the statistical regression methods 
used here account for repeated measurements at different time 
points.
All statistical tests were two-sided with a significance level 
of 5% representing the 95% confidence interval. Data analysis 
was performed using the R software for statistical computing, 
version 3.1.1 (R Foundation for Statistical Computing, Vienna, 
Austria, http://www.R-project.org/). Figure  3 was generated 
using GraphPad Prism 6 software, version 6.0.4.
resUlTs
Patient characteristics
A total of 342 samples have been analyzed from 107 patients (78 
prior to SCT, 264 after SCT), 37 (35%) females, and 70 (65%) 
Table 1 |  Patient’s characteristics.
characteristics Total With acute graft-versus-host disease (agVhD) Without agVhD p
n % n % n %
Patients 107 100 62 100 45 100
age at scT 1
Median (range), years 52.7 (17.5–70.1) 50.3 (24.3–70.7)
sex 0.013
Female 37 35 15 24 22 49
Male 70 65 47 76 23 51
Disease 0.133
ALL 10 9 8 13 2 4
AML 45 42 23 37 22 49
CLL 5 5 5 8 0 0
CML 1 1 1 2 0 0
Lymphoma 10 9 4 6 6 13
MDS 12 11 9 15 3 7
MM 19 18 10 16 9 20
Other 5 5 2 3 3 7
Donor relation 0.191
Unrelated 77 72 48 77 29 64
Related sibling 30 28 14 23 16 36
Donor hla 0.443
Identical 88 82 49 79 39 87
Mismatched 19 18 13 21 6 13
stem cell source 0.627
BM 8 7 4 6 4 9
PBSC 98 92 57 92 41 91
CB 1 1 1 2 0 0
conditioning 0.130
RIC 86 80 46 75 40 89
MA 20 19 15 25 5 11
serotherapy
ATG 58 54 35 56 23 51
graft-versus-host disease (gVhD) prophylaxis 0.927
CsA + MTX 84 79 48 77 36 80
CsA + MMF 19 18 12 19 7 16
Other 4 4 2 4 2 4
There were 107 patients included in this study. The distributions are shown for the underlying diseases, age, stem cell source, serotherapy, and GVHD prophylaxis. The p-value was 
determined using the Fisher-Exact test or the Mann–Whitney test, as appropriate.
SCT, stem cell transplantation; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MDS, 
myelodysplastic syndrome; MM, multiple myeloma; BM, bone marrow; PBSC, peripheral blood stem cells; CB, cord blood; RIC, reduced-intensity conditioning; MA, myeloablative; 
ATG, anti-thymocyte globulin; CsA, cyclosporin A; MTX, methotrexat; MMF, mycophenolate mofetil; p, p-value. p-Value was performed using the Fisher-Exact test or Mann–Whitney 
test as appropriate.
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males, were included in this study. Fifty-five (51%) patients suf-
fered from acute leukemia, 19 (18%) from multiple myeloma, 
12 (11%) from MDS, 10 (9%) from lymphoma, 6 from chronic 
leukemia (6%) and 5 from other diseases (5%), as shown in 
Table 1. The majority of the patients underwent HLA-identical 
allo-SCT (n  =  88, 82%). Thirty patients had related sibling 
donors (28%), 77 had unrelated donors (72%). The stem cell 
source was peripheral blood stem cells in 98 patients (92%), 
bone marrow (BM) in eight patients (7%), and cord blood 
in one patient (1%). A reduced-intensity conditioning (RIC) 
regimen was administered in 86 patients (80%), and 21 patients 
were treated using myeloablative regimens (20%). Fifty-eight 
patients received anti-thymocyte globulin treatment (54%). 
GVHD prophylaxis consisted of CSA +  MTX in 84 patients 
(79%). Others received immunosuppressive monotherapy or 
individual combination treatments (see Table  1). While 45 
(42%) patients did not show signs of aGVHD, 62 (58%) patients 
developed aGVHD (grade 1: n = 22, grade 2: n = 21, grade 3: 
n = 14, grade 4: n = 5) at a median of day 28 (11–182) after 
allo-SCT. Symptoms that led to the classification of aGVHD 
and/or cGVHD were defined according to the NIH criteria as 
recently published (20).
No major difference in age, underlying disease, donor type, 
stem cell source, HLA match, conditioning regimen, and GVHD 
prophylaxis between the GVHD group and the group of patients 
without GVHD was observed. The only parameter contributing 
FigUre 1 | Definition of the cD56highcD16dim and cD56dimcD16high natural killer (nK) cell subsets. Representative FACS dot plots of all CD56+CD3−CD14− 
NK cells from a patient on day 24 post-allogeneic stem cell transplantation without (left) or from a patient on day 28 post-allo-SCT with (right) development of acute 
graft-versus-host disease.
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to a significant difference between the two mentioned groups was 
gender with a higher proportion of male patients in the GVHD 
group (p = 0.013).
The median age of the GVHD group was 52.7 years (17.5–70.1) 
and of the group of patients without signs of aGVHD 50.3 years 
(24.3–70.7). In both groups, the majority of patients suffered 
from AML (49%). Additional underlying diseases are indicated 
in Table 1.
The median survival of the group that did not develop aGVHD 
was 34.1 months (ranging from 0.9 to 93.4 months), whereas the 
median survival of the GVHD group was 21.6 months (ranging 
from 1.2 to 65.7 months). The estimated CI of overall aGVHD 
was 57.9% (95% CI: 48.5–67.30%); the estimated CI for aGVHD 
grade I was 18.88% (95% CI: 11.42–26.34%), 19.73% (95% CI: 
12.2–27.38%) for aGVHD grade II, 13.19% (95% CI: 6.75–19.64%) 
for aGVHD grade III, and 3.76% (95% CI: 0.68–8.78%) for severe 
aGVHD grade IV (Figure S1 in Supplementary Material). A criti-
cal phase with very high numbers of incidences occurred between 
days +25 and +50 after allo-SCT.
nK cell subsets
A density plot gated on all CD56+CD3−CD14− NK cells 
further distinguished two major subsets including immature 
CD56highCD16dim (hereinafter referred to as CD56high) and mature 
cytotoxic CD56dimCD16high NK cells (hereinafter referred to as 
CD56dim). In healthy adult controls, only 12.5 ± 9.6% of all NK 
cells belong to the immature CD56high NK population whereas 
the majority of 83.1 ± 12.2% represents mature CD56dim NK cells 
that coexpress CD16 (data not shown). Importantly, in our study 
cohort, there was no significant preexisting difference in NK cell 
subset distribution prior to allo-SCT among patients that later 
developed GVHD or not (Figure S2 in Supplementary Material). 
The appearance of immature CD56high NK cells that do not yet 
express the Fcγ-receptor CD16 on their surface is indicative of 
an efficient immune reconstitution post-allo-SCT. In this study, 
following allo-SCT, the immature subset of CD56high NK cells was 
highly increased and reached up to 45% of all NK cells in patients 
without aGVHD, but was significantly reduced in patients who 
developed aGVHD (Figure 1).
impact of agVhD on nK cell 
reconstitution
Next, we addressed a possible impact of aGVHD on the NK cell 
numbers and early NK cell reconstitution throughout an observa-
tion period of 200 days after allo-SCT. Patients without any signs 
of aGVHD during the whole observation period had considerably 
higher NK cell numbers than patients who developed aGVHD, 
with significant differences in the CD56high NK cell subset (Figure 
S2 in Supplementary Material). In contrast, there was only a trend 
of reduced numbers of CD4+ T cells around week 12 post SCT, 
but overall numbers of CD3+ T cells did not significantly differ in 
GVHD patients compared to patients without GVHD following 
allo-SCT (Figure S3 in Supplementary Material).
Moreover, as shown in Table  2, the longitudinal analysis of 
the logarithmically transformed numbers of the different NK cell 
subsets revealed a negative association between the occurrence 
of aGVHD and the early expansion of the total NK cell popula-
tion (p =  0.06), and in particular the CD56high NK cell subset 
(p  =  0.009). In contrast, there was no significant correlation 
between the CD56dim NK cell subsets or the calculated ratio of 
CD56dim:CD56high NK cells and aGVHD (Table 2). Furthermore, 
a significant inverse correlation between the severity of aGVHD 
and the frequency of CD56high NK cells during aGVHD could be 
demonstrated by the linear spline mixed effect model (Table 3).
FigUre 2 | association of acute graft-versus-host disease (agVhD) and the immune recovery of cD56high natural killer (nK) cells. Lines represent the 
back-transformed CD56high NK cell numbers estimated from the model. The solid line shows the cell recovery in patients without aGVHD, and the dashed line 
indicates patients with aGVHD and the corresponding 95% confidence interval (left graphic). A fitted model considering aGVHD severity illustrates a significant 
correlation between aGVHD grade and the lower recovery of CD56high NK cells during aGVHD (right graphic). **p < 0.01, ***p < 0.001.
Table 2 | impact of agVhD on immune reconstitution of nK cell subsets 
after allogeneic stem cell transplantation (allo-scT).
beta (se) p-Value
nK cells
aGVHD −0.146 (0.08) 0.061
cD56high
aGVHD −0.219 (0.08) 0.009
cD56dim
aGVHD −0.114 (0.09) 0.194
ratio
aGVHD 0.106 (0.07) 0.158
The table summarizes the results of linear spline regression models with mixed effects 
analyzing the influence of aGVHD on each NK cell subset during the first 200 days 
after allo-SCT. The beta coefficients are given in log10 scale due to previous log10-
transformed NK cell subsets.
NK cells, natural killer cells; CD56high, immature CD14−CD3−CD56highCD16dim NK cells; 
CD56dim, mature CD14−CD3−CD56dimCD16high NK cells; Ratio, ratio CD56dim:CD56high; 
aGVHD, acute graft-versus-host disease; Beta, beta coefficient.
Table 3 | impact of the agVhD grade on the number of cD56high natural 
killer (nK) cells.
cD56high beta (se) p-Value
aGVHD grade 1 0.007 (0.11) 0.94
aGVHD grade II −0.28 (0.10) 0.008
aGVHD grade III −0.48 (0.12) <0.001
aGVHD grade IV −0.43 (0.16) 0.009
The table shows the beta coefficients and corresponding p-values for each aGVHD 
grade with respect to the reference category without aGVHD from a mixed effect 
regression with a linear spline model. Patients with aGVHD grade III or IV showed a 
significantly lower frequency of CD56high NK cells compared to patients with aGVHD 
grade I or II.
aGVHD, acute graft-versus-host disease; Beta, beta coefficient.
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Figure  2 shows the recovery of the CD56high NK subset in 
patients without signs of aGVHD (solid black line) compared to 
patients with aGVHD (dashed black line) and their corresponding 
95% confidence intervals. We observed significantly lower num-
bers of CD56high NK cells in the aGVHD group, suggesting that 
aGVHD might cause impaired CD56high NK cell regeneration in 
the early phase after allo-SCT.
Furthermore, the reconstitution of the CD56high subpopula-
tion was analyzed with regard to the severity of aGVHD. We 
observed a significant correlation between the grade of aGVHD 
and the degree of disturbance of CD56high NK cell reconstitution 
(Figures  2 and 3). There was almost no difference in NK cell 
immune reconstitution between patients with grade I GVHD and 
those without GVHD. In contrast, patients with severe grade of 
aGVHD (III–IV) showed lower numbers of CD56high NK cells in 
comparison to patients with milder forms of aGVHD. In sum-
mary, not only the occurrence but also the severity of aGVHD 
correlated with a delayed reconstitution of the CD56high NK cell 
subset.
impact of steroids
To elucidate the impact of steroid treatment (ST) on NK cell 
recovery, the frequencies of the different NK cell subpopulations 
have been calculated for all patients who developed aGVHD at 
least at one sampling time during the entire observation period 
of 200 days (Figure 3). All data on the NK cell numbers meas-
ured in these GVHD patients have been classified and analyzed 
according to the stage of disease at the given time point, as being 
obtained either before or during development of GVHD and with 
or without ST. Reasons for ST without occurrence of GVHD were 
in most cases inappetence, nausea, gastroenteritis, and weakness 
treated with moderate dosing of prednisolone. Only few patients 
received high dose prednisolone due to, e.g., a severe capillary 
leak, vasculitis, or ARDS. GVHD patients were also treated with 
prednisolone (1 mg/kg BW).
Figure  3 and Table S1 in Supplementary Material show the 
results of the linear regression model with smoothing spline 
performed with the above mentioned disease and treatment 
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Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 595
classifications of all GVHD patients. All results are shown in rela-
tion to measurements at time points without signs of aGVHD and 
without ST that served as base line (=100%) of each individual 
patient. In sum, we observed an additive impact of steroids and 
aGVHD on reconstitution of NK cell subsets. Of note, based on 
these analysis, we can exclude that the before mentioned negative 
impact of aGVHD on the CD56high subpopulation recovery could 
be completely explained by ST.
DiscUssiOn
The complex interplay of NK cells and NK cell subsets with other 
immune cells in the development of aGVHD following allo-SCT 
has mainly been investigated in different animal models, but only 
very few human studies have addressed NK cells thus far (8, 9, 
15–17, 21).
However, following allo-SCT, NK cells are among the first 
lymphocytes to reconstitute and reach normal numbers after 
1–4 months, independent of the stem cell source (17, 19, 22, 23).
In line with our previous preclinical observation that NK 
cell maturation was impaired in mice suffering from aGVHD 
and that only the subset of mature CD11b-expressing NK cells 
efficiently protects from developing aGVHD in a mouse model 
of allogeneic BMT (9), Podgorny et al. investigated a large patient 
cohort and observed a reduction in the number of total and cyto-
toxic NK cells during aGVHD (15). This effect might be due to 
a GVHD-induced destruction of the hematopoietic niche in the 
BM as demonstrated by the effect on B cell reconstitution (24, 25). 
However, this study did not address the impact of aGVHD on 
early NK cell reconstitution.
Notably, NK cells play an important role in the early innate 
immune defense, and a recent report has shown an association of 
the reduced number of total and CD56high NK cells with posten-
graftment infection rates after allo-SCT (26).
In our study, we analyzed 342 samples of 107 patients before 
and after allo-SCT for a possible association between aGVHD 
and NK cell numbers including subset composition at different 
time points during the first 200 days following allo-SCT.
To our knowledge, our data are the first to demonstrate that 
aGVHD correlates not only with reduced numbers of total NK 
cells but specifically with the disturbed regeneration of CD56high 
NK cells early after allo-SCT. Patients without any aGVHD dur-
ing the whole observation period had a higher number of NK 
cells and specifically the CD56high NK cell subset than patients 
who developed aGVHD (Table  2; Figure S2 in Supplementary 
Material), while T cell numbers did not significantly differ (Figure 
S3 in Supplementary Material).
Furthermore, we performed a longitudinal analysis to inves-
tigate the impact of aGVHD on early NK cell reconstitution 
(Tables 2 and 3). Remarkably, we found a significant correlation 
between the severity of aGVHD and the degree of disturbance 
of CD56high NK cells during aGVHD (Figure  2; Table  3). As 
described before (15), we also found a non-significant trend 
toward a decrease in total and cytotoxic CD56dim NK cells. A 
 possible explanation for differences in comparison to other 
studies might be the study design and classification of patients 
according to severity of aGVHD (27).
In summary, our data suggest a negative impact of aGVHD on 
early NK cell reconstitution and maturation resulting in a disturbed 
NK cell subset composition. Interestingly, these developments 
seemed to take place regardless of the immunosuppressive effect 
of ST (Figure 3; Table S1 in Supplementary Material). Of note, 
it cannot be excluded that negative effects of steroids on NK cell 
reconstitution might influence the risk of GVHD post-allo-SCT.
FigUre 3 | impact of steroid application on natural killer (nK) cell subset distribution. Linear spline model including all patients that developed acute 
graft-versus-host disease at least at one measurement during the entire observation period after allogeneic stem cell transplantation (allo-SCT). All NK cell data were 
classified into four categories according to the stage of graft-versus-host disease (GVHD) (before or during/after GVHD) and the treatment with steroids [steroid 
treatment (ST) or no ST]. The bars illustrate the frequency of each NK cell subset related to the respective estimate regression coefficients for that specific subset 
compared to that of patients before GVHD development and without ST (100% reference). *p < 0.05, and ***p < 0.001. Ψ related to estimated coefficients.
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